NASDAQ:HSCS HeartSciences Q3 2025 Earnings Results & Report $2.06 -0.02 (-0.96%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$2.24 +0.18 (+8.79%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. HeartSciences missed analyst earnings expectations in its Q3 2025 results, released March 13, 2025. The company reported EPS of -$2.5722 versus the -$2.53 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateMarch 13, 2025TimeBefore Market OpensConference Call8:00 AM ET HeartSciences EPS ResultsActual EPS-$2.5722Consensus EPS -$2.53Beat/MissMissed by -$0.0422One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersHeartSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsHeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) HeartSciences Q3 2025 Earnings FAQ Did HeartSciences beat earnings estimates for Q3 2025? HeartSciences (NASDAQ:HSCS) reported earnings of -$2.5722 per share for Q3 2025, missing the consensus estimate of -$2.53. The report was announced on Thursday, March 13, 2025. When is HeartSciences' next earnings date? HeartSciences' next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for HeartSciences on the company's earnings history page. HeartSciences Earnings HeadlinesFortitude Reports Financial and Operating Results for the Nine Months Ended September 30, 2026November 16 at 7:30 AM | globenewswire.comHeartSciences (NASDAQ:HSCS) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?November 7, 2026 | americanbankingnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 18 at 1:00 AM | Porter & Company (Ad)HeartSciences Adds Supplemental Disclosures to Merger Proxy StatementNovember 6, 2026 | tipranks.comHeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude MiningOctober 21, 2026 | globenewswire.comHeartSciences Wins FDA Clearance For MyoVista WavECG; Fortitude Lines Up $100 Mln Miner DealOctober 6, 2026 | rttnews.comSee More HeartSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email. Email Address About HeartSciencesHeartSciences (NASDAQ:HSCS) develops medical technology intended to help healthcare professionals detect heart conditions using electrocardiograms (ECGs). The company combines ECG testing with software-based analysis to support the assessment of cardiac function. Its MyoVista wavECG device is designed to perform standard ECG testing while also analyzing the heart’s electrical signals for information that may help identify dysfunction, including diastolic dysfunction. The company’s offerings are aimed at clinical settings where ECGs are used to evaluate patients’ heart health. HeartSciences focuses on developing and commercializing these technologies for healthcare providers. Its products are intended to complement existing diagnostic workflows; medical professionals determine how results are interpreted and used in patient care.View HeartSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a BreakoutAmazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be Building Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.